Trial Profile
A postmarketing clinical study of milnacipran hydrochloride (MIL001) for the treatment of depression. -a double-blind parallel-group design, using a comparator of paroxetine hydrochloride hydrate-
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2016
Price :
$35
*
At a glance
- Drugs Milnacipran (Primary) ; Paroxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Asahi Kasei Pharma Corp
- 25 May 2016 New trial record